Press Release

Harbour BioMed Announces IND Clearance for Novel G Protein-coupled Receptor HBM1022 Targeting CCR8 in the U.S.

February 07, 2023

Follow
Harbour BioMed
on WeChat

Back to list

Harbour BioMed Announces IND Clearance for Novel G Protein-coupled Receptor HBM1022 Targeting CCR8 in the U.S.

February 07, 2023
  • HBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform
  • HBM1022 presented cynomolgus cross-reactive and demonstrated its anti-tumor functional activities in preclinical studies
  • HBM1022 is expected to present therapeutic potentials in a variety of solid tumors with enriched CCR8-positive Tregs, including breast cancer, colon cancer, gastric cancer, non-small cell lung cancer and head and neck cancer

 

Cambridge, MA, Rotterdam, NL, Suzhou, CN— February 7, 2022

 

Harbour BioMed (Company, HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration of the United States (FDA) to initiate clinical trials in the U.S. for monoclonal antibody HBM1022.

 

HBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform. The antibody can enhance anti-tumor immunity by depleting CCR8 positive regulatory T cells, activating effector T cells. HBM1022 presented cynomolgus cross-reactive and demonstrated its anti-tumor functional activities in preclinical studies.

 

CCR8 is a novel G protein-coupled receptor (GPCR) target on tumor-specific Treg cells. GPCRs are essential in immunoregulation, especially for immuno-oncology, where numerous chemokines work through GPCRs. It has been extremely challenging to develop due to the structural complexity and low immunogenicity. CCR8 is expressed enhanced in tumor infiltrated Treg cells, and functional involved in Treg cells migration and infiltration. Tumor resident CCR8 positive Treg have been shown to be a major driver for immunosuppression.

 

Generated from the Company's platform, HBM1022 is one of the few functional monoclonal antibodies that can be cross-reactive to human and cynomolgus CCR8 with GPCR signaling modulation. With its unique characteristics, HBM1022 is expected to present therapeutic potentials in a variety of solid tumors with enriched CCR8-positive Tregs, including breast cancer, colon cancer, gastric cancer, non-small cell lung cancer and head and neck cancer.

 

About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
 
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, HBICE® with single B cell cloning platform, the antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com

Media Contact:

Harbour BioMed Public Relations

E-mail: pr@harbourbiomed.com